We are live on ! Find out more
ASH icon

Ashland

74.32 USD
+0.56
0.76%
At close Updated Aug 26, 4:00 PM EDT
Pre-market
After hours
74.32
0.00
0%
1 day
0.76%
5 days
3.83%
1 month
11.96%
3 months
28.45%
6 months
19.35%
Year to date
24.18%
1 year
32.5%
5 years
-13.33%
10 years
31.61%
 

About: Ashland Inc. is a specialty materials company serving markets including pharmaceuticals, personal care, food and beverages, coatings, construction, energy, and electronics. It operates through four segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. Life Sciences contributes the highest revenue, offering functional additives for pharmaceutical and nutrition applications. Personal Care provides ingredients for skin, hair, oral care, and household products, while Specialty Additives supplies performance-enhancing additives for coatings and. Intermediates produce BDO and related derivatives used in polymers, electronics, agriculture, and pharmaceutical applications. The company generates sales across North America, Europe, Asia Pacific, Latin America, and regions.

Employees: 2,900

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 28.6%
Neutral 52.4%
Negative 19%
Neutral
Zacks Investment Research
1 day ago
ASH Launches Permexa Sodium Caprate to Support Oral Biologics Growth
Ashland launches Permexa sodium caprate to support oral peptide and biologic development with enhanced processing and permeability.
ASH Launches Permexa Sodium Caprate to Support Oral Biologics Growth
Neutral
GlobeNewsWire
2 days ago
Ashland advances high-growth oral biologics delivery applications with launch of permexa™ sodium caprate
WILMINGTON, Del., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH), is announcing the launch of permexa™ sodium caprate, a high-performance intestinal permeation enhancer designed to support the scalable development and commercialization of oral peptide, biologic and low-permeability drug products, including rapidly expanding GLP-1 agonists and related therapeutic pipelines.
Ashland advances high-growth oral biologics delivery applications with launch of permexa™ sodium caprate
Positive
Seeking Alpha
13 days ago
Ashland Inc.: Activist Pressure Starts To Pay Off
Ashland Inc. (ASH) remains a Buy, with the investment case now centered on activist-driven M&A potential and strategic alternatives. Life Sciences and Personal Care segments, comprising 82% of gross EBITDA, continue to deliver growth and margin stability, underpinning valuation. Multiple activist investors, including Standard Industries and Ancora, have driven board changes, capital allocation reviews, and engagement with potential acquirers.
Ashland Inc.: Activist Pressure Starts To Pay Off
Neutral
GlobeNewsWire
19 days ago
Ashland board authorizes quarterly dividend
WILMINGTON, Del., Aug. 07, 2026 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.42 cents per share on the company's common stock.
Ashland board authorizes quarterly dividend
Neutral
Seeking Alpha
27 days ago
Ashland Inc. (ASH) Q3 2026 Earnings Call Transcript
Ashland Inc. (ASH) Q3 2026 Earnings Call Transcript
Ashland Inc. (ASH) Q3 2026 Earnings Call Transcript
Neutral
MarketBeat
28 days ago
Ashland Q3 Earnings Call Highlights
Ashland NYSE: ASH reported higher sales across all four business units in its fiscal third quarter of 2026, supported by volume growth, pricing actions and demand in its Life Sciences and Personal Care operations. The company reaffirmed its full-year sales and adjusted EBITDA outlook, while lowering its adjusted earnings-per-share growth forecast because of a higher tax rate tied to unfavorable discrete items.
Ashland Q3 Earnings Call Highlights
Positive
Benzinga
28 days ago
Ashland Analysts Increase Their Forecasts After Strong Q2 Results
Ashland Inc (NYSE:ASH) on Tuesday posted better-than-expected earnings for the second quarter.
Ashland Analysts Increase Their Forecasts After Strong Q2 Results
Neutral
Zacks Investment Research
28 days ago
Ashland's Q3 Earnings Miss Estimates, Sales Beat on Volume Growth
ASH's Q3 sales beat estimates as volume growth lifted all segments, but adjusted earnings missed and the company lowered its fiscal 2026 EPS growth outlook.
Ashland's Q3 Earnings Miss Estimates, Sales Beat on Volume Growth
Negative
Zacks Investment Research
29 days ago
Ashland (ASH) Q3 Earnings Lag Estimates
Ashland (ASH) came out with quarterly earnings of $1.02 per share, missing the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $1.04 per share a year ago.
Ashland (ASH) Q3 Earnings Lag Estimates
Positive
Zacks Investment Research
29 days ago
Ashland (ASH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Ashland (ASH) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ashland (ASH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Price charts implemented using Lightweight Charts™